Article Text

other Versions

Download PDFPDF
Short report
Drug interaction between bortezomib and tuberculosis treatment: a case report
  1. Pascale Cuny1,
  2. Anne Marfaing-Koka2,
  3. Marion Lottmann3,
  4. André Rieutord1,
  5. Severine Barbault-Foucher1
  1. 1Pharmacy Unit, Beclere Hospital (AP-HP), Clamart, France
  2. 2Department of Haematology, Beclere Hospital (AP-HP), Clamart, France
  3. 3Pharmacovigilance Regional Center, Georges Pompidou European Hospital (AP-HP), Paris, France
  1. Correspondence to Pascale Cuny, Pharmacy Unit, APHP, HUPS, Antoine Béclère Hospital, 157 rue de la porte de Trivaux, Clamart 92140, France; pasccuny{at}


An adult patient was diagnosed with plasmacytoma and monoclonal gammopathy. An increase in IgG λ and myeloma stage IIIa without cytogenetic abnormalities was found. The patient was treated with dexamethasone, bortezomib and pegylated liposomal doxorubicin. A decrease in monoclonal protein was observed during the first four cycles of chemotherapy. Isoniazid and rifampicin were introduced following suspected tuberculosis. Then, an increase in monoclonal gammopathy led to the combination of lenalidomide and chemotherapy. The persistent increase in the monoclonal component suggested a possible interaction between rifampicin and bortezomib. Tuberculosis treatment was stopped and a decrease in monoclonal protein during subsequent courses and regression of lesions on CT scan images confirmed this interaction to be likely. To our knowledge, this is the first report of concomitant administration of bortezomib with rifampicin. Therefore, a potential interaction between bortezomib and rifampicin should be anticipated during concomitant administration in the future.

  • Immunology

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.